Zeist, July 7 2021
After five years of dedication, Aize Smink, CEO of Julius Clinical the Science CRO, has decided to pursue new career opportunities. Julius Clinical is very grateful to Aize for his leadership and passion. Aize managed several major studies and expanded our portfolio to include new therapeutic domains and the inclusion of real world evidence and data science. He leaves Julius Clinical with a solid base for further growth and ready for new opportunities.
We are pleased to announce the appointment of Martijn Wallert as successor and Chief Executive Officer of the company. Martijn has worked for Julius Clinical in the past as Director Strategic Partners and, after advancing his career internationally, he will now bring his experience to step into the CEO position. We are confident that our clients and partners across the globe will welcome our new CEO and continue to collectively create research that impacts patients and society.
For inquiries, please contact Julius Clinical at:
+31 30 656 9900